TGFbeta Antagonists, Including AT1 Receptor Blockers, Rescue the Multisystem Pathogenesis of Marfan Syndrome & Associated Mouse Model
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Marfan syndrome / connective tissue disorder (emphysema, cardiovascular, skeletal)
Modality
Monoclonal Antibody
Mechanism
TGF-beta antagonist / AT1 receptor blocker
Target
TGFB1
rNPV Envelope
Low
-$16.6M
costs +25% · peak −25%
Base
-$13.1M
cumulative PoS 0.8%
High
-$9.6M
costs −25% · peak +25%
This is a conservative illustrative profile only. The actual asset is a basic-science discovery and generic-drug repositioning story; the clinical translation already occurred through losartan trials and was underwhelming versus atenolol, so product-style PoS is intentionally low.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.70
Modality fit · 30%
0.51
Whitespace · 30%
0.50
Composite 0.584 — composite-score rank #30 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#9) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Losartan / angiotensin II type 1 receptor blockade in Marfan syndrome
Direct clinical translation of the Dietz/Habashi/Cohn discovery: AT1 blockade can modulate TGF-beta signaling in Marfan models. It is generic drug repositioning, not a novel antibody product.
Criteria 1 and 2: same mechanism family and indication; commercial value limited by generic status.
Atenolol comparator in Pediatric Heart Network Marfan trial
Clinical standard comparator from the NEJM randomized trial where losartan was not superior to atenolol on aortic-root dilation rate, creating the key translation caveat.
Criteria 2 and 3: same indication and trial endpoint; used as clinical translation reality check.
TGF-beta neutralization in Marfan mouse models
Mechanism anchor from the original discovery showing TGF-beta antagonism rescues mouse phenotypes. This is a scientific comparator, not a developable mAb anchor.
Criteria 1: same pathway biology; non-clinical and not a commercial mAb comparator.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $5.0M | 18 mo | 25.0% | [0] [1] |
| Phase I | $18.0M | 12 mo | 50.0% | [1] [2] |
| Phase II | $55.0M | 30 mo | 20.0% | [2] [3] |
| Phase III | $130.0M | 42 mo | 38.0% | [2] [3] |
| NDA/BLA Review | $8.0M | 12 mo | 82.0% | [2] |
Multiplier handling: Eligible multipliers (genetic_disease_biology) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$50.0M peak · WACC 14.0%
Peak revenue. Losartan and atenolol are generic and the discovery does not create a proprietary therapeutic. The $50M illustrative peak is a placeholder for a hypothetical niche partnered TGF-beta-modulating follow-on, not a forecast for AT1 blockers.
WACC. The science is strong, but the commercial asset is weak because the translational path is generic/off-patent and clinically modest.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$13.1M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$61.1M
P25
-$11.0M
P50 (median)
-$4.9M
P75
-$3.0M
P95
-$1.7M
Prob ≥ 0
0.0%
Evidence register
4 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU page frames TGF-beta antagonists/AT1 blockers as the Marfan invention cmo_findings.asset_class_reality | TGFbeta Antagonists, Including AT1 Receptor Blockers, Rescue the Multisystem Pathogenesis of Marfan Syndrome regulatory | 2014-10-07 | high |
Original losartan/TGF-beta Marfan mouse discovery comparators[0] | Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome peer_review | 2006-04-07 | high |
Losartan clinical translation was not superior to atenolol stage_profile.phase_2.pos | Atenolol versus losartan in children and young adults with Marfan's syndrome peer_review | 2014-11-27 | high |
Clinical trial identifier for Marfan losartan comparison comparators[1] | Pediatric Heart Network Marfan losartan trial trial_disclosure | 2014-11-27 | high |
Thesis
Why this asset earns its rank
This is a basic-science discovery and generic-repositioning story, not a novel mAb. The Dietz/Habashi/Cohn work linked excess TGF-beta signaling to Marfan syndrome pathology and showed that AT1 blockade with losartan could rescue mouse-model disease biology. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial.
The comparator evidence is scientifically important but commercially adverse. Losartan is generic, atenolol is generic, and the major Pediatric Heart Network trial found losartan roughly comparable to atenolol rather than transformational. The engine result is -$16.6M to -$9.6M, with a base rNPV of -$13.1M and cumulative PoS of 0.8%; that low illustrative spread is appropriate because the real value is reputational/scientific and clinical-practice influence, not a proprietary biotech product.
Verdict: landmark translational biology, poor standalone commercialization. It earns its rank because Marfan is clinically important and the discovery influenced care, but a CMO would immediately reject a novel-antibody or full-product rNPV framing.
Key risks
Asset-specific, not generic biotech risks
- Asset-class mismatch: the strongest translation is losartan/AT1 blockade, a generic small molecule, not a proprietary TGF-beta mAb.
- Clinical translation was underwhelming: losartan did not clearly beat atenolol in the pivotal Pediatric Heart Network trial.
- Patent/commercial moat risk: old discovery and generic agents leave little defensible product economics for JHTV.
- Mechanism risk: systemic TGF-beta antagonism is pleiotropic and hard to turn into a safe chronic biologic for Marfan.